BreezeBio Presents Data Supporting NanoGalaxy® Platform for Antigen-Specific Immune Tolerance in Type 1 Diabetes at ADA 2026
Data support BreezeBio’s hydrophilic nanoparticle mRNA-based approach for targeted
delivery to antigen-presenting cells and induction of immune tolerance
BRISBANE, Calif., June 9, 2026, BreezeBio, Inc., formerly known as GenEdit, today announced data presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) supporting its NanoGalaxy® hydrophilic nanoparticle platform for antigen-specific immune tolerance in type 1 diabetes. The pre-clinical data show that NanoGalaxy can deliver mRNA-encoded disease-relevant antigens and tolerogenic co-payloads to antigen-presenting cells, supporting induction of antigen-specific regulatory T cells and providing the scientific foundation for BRZ-101, BreezeBio’s lead therapeutic candidate in type 1 diabetes.
“Type 1 diabetes is driven by an autoimmune attack on insulin-producing beta cells, creating a need for therapeutic approaches that can address the underlying immune response while preserving broader immune function,” said J. Rodrigo Mora, M.D., Ph.D., Chief Scientific Officer of BreezeBio. “These data support a targeted mRNA-based strategy designed to deliver disease-relevant antigens and tolerogenic signals to antigen-presenting cells, with the goal of restoring immune tolerance in a disease-specific manner.”
NanoGalaxy® hydrophilic nanoparticles are designed for targeted tissue delivery and tunable immunogenicity. In the ADA presentation, BreezeBio showed that NanoGalaxy hydrophilic nanoparticles can de-target the liver and deliver mRNA to spleen antigen-presenting cells, including conventional dendritic cells and macrophages. The platform also demonstrated the ability to deliver multiple mRNA payloads, including disease-relevant antigens and tolerogenic co-payloads, to support induction of antigen-specific regulatory T cells.
The data were presented at ADA 2026 by Dr. Mora in a presentation titled, NanoGalaxy®, a Novel Hydrophilic Nanoparticle mRNA-Based Platform to Induce Immune Tolerance in Type 1 Diabetes.
About BRZ-101
BRZ-101 is BreezeBio’s lead therapeutic candidate for type 1 diabetes and is designed to deliver mRNA encoding autoantigens together with a tolerogenic co-payload to antigen-presenting cells. By presenting these antigens to T cells in the context of tolerance, BRZ-101 is intended to induce antigen-specific regulatory T cells, reduce pathogenic immune activity, and help protect pancreatic beta cells from autoimmune destruction.
About BreezeBio
BreezeBio is a biotechnology company developing genetic medicines enabled by precise, non-viral delivery across biologically relevant tissues. Using its proprietary NanoGalaxy® platform, BreezeBio engineers nanoparticles designed to deliver genetic payloads, including mRNA, to specific cell types, with demonstrated delivery to immune cells as well as select tissues in the heart, lung, and central nervous system. The company is advancing an internal therapeutic pipeline focused on autoimmune diseases and oncology, led by BRZ-101 to restore immune tolerance in type 1 diabetes. BreezeBio is headquartered in California in the South San Francisco area. For more information, visit www.breezebio.com.
Contacts
Corporate: Kunwoo (Ryan) Lee, Ph.D., [email protected]
Media: Jason Glashow, Glashow Strategic Communications, [email protected]
